Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Short Interest Update

Basilea Pharmaceutica AG (OTCMKTS:BPMUF) was the target of a large decrease in short interest in March. As of March 31st, there was short interest totalling 100 shares, a decrease of 95.2% from the March 15th total of 2,100 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average trading volume of 100 shares, the days-to-cover ratio is currently 1.0 days.

Basilea Pharmaceutica Stock Performance

BPMUF remained flat at $51.00 during trading on Wednesday. The firm’s fifty day moving average price is $53.15 and its two-hundred day moving average price is $52.84. Basilea Pharmaceutica has a fifty-two week low of $51.00 and a fifty-two week high of $54.00. The company has a debt-to-equity ratio of 5.70, a current ratio of 4.10 and a quick ratio of 3.27.

Basilea Pharmaceutica Company Profile

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.